Believe the pharmaceutical industry has been paying increasing attention to the potential of Fixed-Dose Combination products, and in a series of three articles, examine the past, present, and future of these products with the intent of understanding their whats and whys. (Drug Development & Delivery, March 2014)
Tugrul T. Kararli, PhD, MBA, Kurt Sedo, and Josef Bossart, PhD, believe the pharmaceutical industry has been paying increasing attention to the potential of Fixed-Dose Combination products, and in a series of three articles, examine the past, present, and future of these products with the intent of understanding their whats and whys.
FIXED-DOSE COMBINATIONS - Fixed-Dose Combination Products - What’s in the Clinic? (Part 3 – Pipeline)
In the first two parts of this series, we looked at the past and present situation with regard to fixed-dose combination (FDC) products. In this concluding article, we will take a peek at what’s in the pipeline.
"Latest Trends in Drug Delivery" presented by Dr. T. Kararli at the SMi Controlled Release conference in London, UK - March 2014.
Approved Products 2000 to 2009 Josef Bossart, PhD; Kurt Sedo; and Tugrul T. Kararli, PhD, MBA; review what Drug Delivery has "delivered" in the past decade. An important perspective is provided by looking at drug delivery products approved by the FDA in the past decade.
Contract Pharma has published the PharmaCircle article - "Injectables - The New Oral?" in their April issue. The article is loosely based on Tugrul Kararli's presentation at PODD (Partnership Opportunities in Drug Delivery) last October. The article is built on PharmaCircle data that suggests Injectables have become a delivery route of significant interest for Pharma and Specialty Pharma companies.
Reducing misuse and abuse is one of the more interesting applications of formulation and drug delivery technology to real-world challenges. We decided it would be interesting to interrogate the PharmaCircle database and see what successes have been achieved with respect to abuse-deterrent formulations in terms of approved and pipeline products. We also took a more general look at the formulation approaches being applied to abuse deterrence.